Yvette Naranjo
Acute Care · Miami, FLNPI 1255806170
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 404 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,230, 2.3 times the $1,382 reported in 2021. Among acute care clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 404 payments — averaging $29.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$2K
- Boehringer Ingelheim$2K
- Actelion Pharmaceuticals US, Inc.$564
- Mallinckrodt Hospital Products Inc.$521
- Sanofi$485
- plus $4K from 29 others
What the payments were for
- Food & beverage$11,957100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 105 | $2,621 |
| AstraZeneca | 57 | $2,401 |
| Boehringer Ingelheim | 54 | $1,840 |
| Actelion Pharmaceuticals US, Inc. | 23 | $564 |
| Mallinckrodt Hospital Products Inc. | 25 | $521 |
| Sanofi | 14 | $485 |
| Insmed, Inc. | 18 | $447 |
| Verona Pharma, Inc. | 17 | $378 |
| Regeneron Healthcare Solutions, Inc. | 17 | $322 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $308 |
| Smith+Nephew | 3 | $229 |
| Baxter Healthcare | 8 | $184 |
| Mylan Specialty L.p. | 7 | $163 |
| Stryker | 1 | $132 |
| Hollister Incorporated | 2 | $126 |
| Vertex | 1 | $124 |
| Solventum Corporation | 1 | $120 |
| Medical Device Business Services, Inc. | 1 | $117 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $110 |
| United Therapeutics Corporation | 4 | $106 |
| Bayer | 4 | $101 |
| Merck | 3 | $96 |
| Paratek Pharmaceuticals, Inc. | 5 | $92 |
| Amgen | 4 | $64 |
| Advanced Respiratory, Inc | 3 | $60 |
| Lilly USA, LLC | 3 | $50 |
| Philips North America LLC | 3 | $48 |
| Vifor Pharma, Inc. | 1 | $28 |
| Viatris Specialty LLC | 1 | $25 |
| Liquidia Technologies, Inc. | 1 | $23 |
| AbbVie | 1 | $17 |
| Optinose US, Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Pinnacle Biologics, Inc | 1 | $12 |
| Johnson & Johnson | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,957 in reported general payments places this provider in the 95th percentile of 1,150 acute care providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 880 | $592,636 |
| Breo ElliptaFluticasone/Vilanterol | 393 | $166,462 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 179 | $117,753 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 51 | $30,718 |
| SymbicortBudesonide/Formoterol Fumarate | 53 | $16,512 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 516 | $11,323 |
| EliquisApixaban | 13 | $9,939 |
| Fluticasone Propionate | 410 | $6,915 |
| Wixela InhubFluticasone Propion/Salmeterol | 73 | $5,821 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 21 | $4,424 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 31 | $3,562 |
| Azelastine Hcl | 63 | $1,899 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 28 | $1,687 |
| Ventolin HfaAlbuterol Sulfate | 26 | $1,449 |
| Montelukast Sodium | 91 | $623 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $2,621 | $789,8161,324 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,401 | $134,265232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,150 acute care providers in Florida.
Other acute care in Miami
- Yuri CarmonaMiami$10K
- Monica RamirezMiami$9K
- Rosa Canete-YohamMiami$9K
- Julio AcostaMiami$9K
- Uday DasariMiami$7K
- Julissa WilliamsMiami$7K
- Michelle ViteriMiami$6K
- Marie RenoitMiami$6K
- Rebecca JuliaoMiami$5K
- Lissette Gomez-RiosMiami$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.